Though excipients are a necessary drug component that can often be taken for granted, the ever-changing pharma landscape is always pushing us to shift our perspectives.
Companies prioritizing optimized synthetic routes, stable API forms, and verified analytical tools set the stage for phase I clinical manufacturing success
Sarepta Therapeutics announced that the U.S. FDA has removed the clinical hold on the company's investigational peptide-conjugated phosphorodiamidate morpholino oligomer to treat...